Kalaris Therapeutics (KLRS) Competitors $2.58 -0.03 (-1.15%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock KLRS vs. PROK, ALMS, ELDN, CYBN, TIL, PBYI, VYGR, TLSA, IMAB, and LFVNShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include ProKidney (PROK), Alumis (ALMS), Eledon Pharmaceuticals (ELDN), Cybin (CYBN), Instil Bio (TIL), Puma Biotechnology (PBYI), Voyager Therapeutics (VYGR), Tiziana Life Sciences (TLSA), I-Mab (IMAB), and Lifevantage (LFVN). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors ProKidney Alumis Eledon Pharmaceuticals Cybin Instil Bio Puma Biotechnology Voyager Therapeutics Tiziana Life Sciences I-Mab Lifevantage ProKidney (NASDAQ:PROK) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment. Does the media prefer PROK or KLRS? In the previous week, ProKidney had 62 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 62 mentions for ProKidney and 0 mentions for Kalaris Therapeutics. ProKidney's average media sentiment score of 0.13 beat Kalaris Therapeutics' score of 0.00 indicating that ProKidney is being referred to more favorably in the media. Company Overall Sentiment ProKidney Neutral Kalaris Therapeutics Neutral Which has more volatility & risk, PROK or KLRS? ProKidney has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in PROK or KLRS? 51.6% of ProKidney shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer PROK or KLRS? ProKidney currently has a consensus price target of $3.50, suggesting a potential downside of 6.17%. Given ProKidney's stronger consensus rating and higher possible upside, research analysts clearly believe ProKidney is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProKidney 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Kalaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PROK or KLRS more profitable? ProKidney's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProKidneyN/A N/A -15.03% Kalaris Therapeutics N/A -62.08%-54.69% Which has higher earnings and valuation, PROK or KLRS? Kalaris Therapeutics has lower revenue, but higher earnings than ProKidney. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProKidney$80K13,647.14-$61.19M-$0.60-6.22Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A SummaryProKidney beats Kalaris Therapeutics on 9 of the 12 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.81M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E RatioN/A20.8027.0020.10Price / SalesN/A286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book0.117.487.985.56Net Income-$58.77M-$55.04M$3.16B$248.40M7 Day Performance0.78%2.44%2.40%4.67%1 Month Performance-15.69%1.90%2.19%6.64%1 Year PerformanceN/A4.35%33.82%21.31% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris TherapeuticsN/A$2.58-1.1%N/AN/A$48.81MN/A0.00110Positive NewsGap UpPROKProKidney0.7354 of 5 stars$0.69+19.1%$3.50+408.0%+68.8%$186.51M$80K-1.153Trending NewsGap UpHigh Trading VolumeALMSAlumis2.8917 of 5 stars$3.29+0.2%$22.86+595.8%N/A$184.98MN/A0.00N/AELDNEledon Pharmaceuticals2.5357 of 5 stars$3.01-1.8%$9.00+199.5%+38.5%$184.44MN/A-1.4310CYBNCybin2.9135 of 5 stars$7.98+8.1%$86.00+978.4%N/A$182.81MN/A-1.8250Analyst ForecastTILInstil Bio3.1213 of 5 stars$28.23+18.6%$119.00+321.5%+130.6%$180.37MN/A-2.36410High Trading VolumePBYIPuma Biotechnology3.7821 of 5 stars$3.55-0.3%$7.00+97.2%+20.5%$177.68M$230.50M4.61200VYGRVoyager Therapeutics3.8028 of 5 stars$3.28+2.5%$13.39+308.2%-59.2%$177.08M$66.96M-2.25100TLSATiziana Life Sciences0.81 of 5 stars$1.54-1.9%N/A+81.6%$176.44MN/A0.008IMABI-Mab2.8748 of 5 stars$2.23-2.6%$6.00+169.1%+41.0%$175.57M$3.89M0.00380Gap UpLFVNLifevantage4.2731 of 5 stars$12.53-6.5%$30.50+143.5%+156.3%$172.71M$200.16M18.15260 Related Companies and Tools Related Companies PROK Competitors ALMS Competitors ELDN Competitors CYBN Competitors TIL Competitors PBYI Competitors VYGR Competitors TLSA Competitors IMAB Competitors LFVN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KLRS Stock Alerts